← All trials
NCT06664775
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 25, 2024
- Primary completion
- Jul 31, 2025
- Completion date
- Aug 31, 2025
- First posted
- Oct 30, 2024
- Last posted
- Oct 30, 2024
- Enrollment
- 116
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Corza Medical GmbHLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.